Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-21
2005-06-21
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S092000, C549S399000
Reexamination Certificate
active
06908917
ABSTRACT:
This invention provides compounds defined by Formula Ior a pharmaceutically acceptable salt thereof,wherein R1, Q, Y2, Y3, Y4, U5, U6, U8, and R2are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.
REFERENCES:
patent: 6008243 (1999-12-01), Bender et al.
patent: 6656932 (2003-12-01), Picard et al.
patent: 2002/0151555 (2002-10-01), Barvian et al.
patent: 2002/0151558 (2002-10-01), Andrianjara et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2002/0156069 (2002-10-01), Picard et al.
patent: 2002/0161000 (2002-10-01), Barvian et al.
patent: 2002/0193377 (2002-12-01), Andrianjara et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2003/0078276 (2003-04-01), Andrianjara et al.
patent: 2003/0087924 (2003-05-01), Sorenson
patent: 2003/0130278 (2003-07-01), Gaudilliere et al.
patent: 2003/0144274 (2003-07-01), Bunker et al.
patent: 2003/0216402 (2003-11-01), Gaudilliere et al.
patent: 2003/0220355 (2003-11-01), Gaudilliere et al.
patent: 2004/0006077 (2004-01-01), Gaudilliere et al.
patent: 0 935 963 (1999-08-01), None
patent: 1 138 680 (2001-10-01), None
patent: WO 00/09485 (2000-02-01), None
patent: WO 01/12611 (2001-02-01), None
patent: WO 01/63244 (2001-08-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064568 (2002-08-01), None
patent: WO 02/064571 (2002-08-01), None
patent: WO 02/064572 (2002-08-01), None
patent: WO 02/064578 (2002-08-01), None
patent: WO 02/064595 (2002-08-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 02/064599 (2002-08-01), None
patent: WO 03/032999 (2003-04-01), None
patent: WO 03/033478 (2003-04-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 04/000322 (2003-12-01), None
Vincenti et al. {Arthritis Res. 2002; 4(3):157-64}.
Skotnicki JS et al., {Curr. Opin. Drug Discov. Devel. Sep.; 2003 6(5): 742-59}.
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
U.S. Appl. No. 10/634,531, filed Aug. 5, 2003, Johnson.
U.S. Appl. No. 10/634,709, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,162, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,473, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,289, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,180, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,712, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,181, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,489, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,420, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,716, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,288, filed Aug. 5, 2003, O'Brien.
U.S. Appl. No. 10/634,717, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,177, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,290, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,182, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,419, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,713, filed Aug. 5, 2003, Picard.
U.S. Appl. No. 10/634,225, filed Aug. 5, 2003, Picard et al.
U.S. Appl. No. 10/739,261, filed Dec. 18, 2003, Bunker et al.
Hirota, et al., “Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]-pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative coupling”, Heterocycles, 1994; 37(1):563-570.
Chen, et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J.Am.Chem.Soc., 2000; 122, 9648-9654.
Lovejoy, et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biol., 1999; 6:217-221.
Moy, et al., High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMp-13) complexed with a hydroxamic acid inhibitor, J. Mol. Biol., 2000; 302:671-689.
Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Active of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996; 97(3):761-768.
Neuhold, et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001; 107: 35-44.
Dahlberg, et al., Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase I (Matrix Metalloproteinase 1), Arthrit. & Rheum., 2000; 43(3): 673-682.
Billinghurst, et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleuken-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthrit. & Rheum., 2000; 43(3): 664-672.
Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997; 99:1534-1545.
Office Action Mailed Jun. 16, 2003 in U.S. Appl. No. 10/264,764 (PC20536A).
Freemont, et al., “In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage”, Ann. Rheum. Dis. 1999; 58:357-365.
Reboul, et al., “the New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes”, J.Clin.Invest., 1996; 97(9):2011-2019.
Wernicke, et al., “Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoid Arthritis and Osteoarthritis”, J. Rheum. 1996; 23(4):590-595.
Ashbrook Charles W.
Berch Mark L.
Habte Kahsay
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Chromone derivatives as matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromone derivatives as matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromone derivatives as matrix metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474117